SemBioSys eligible to proceed with Phase I/II plant-produced insulin trial after submiss... (ourth quarterof 2008. Prior to proceedin...)

SemBioSys eligible to proceed with Phase I/II plant-produced insulin trial after submission of IND

Date:9/16/2008

ourth quarter of 2008. Prior to proceeding with the trial the company must await clearance from the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom. SemBioSys' planned Phase I/II human clinical trial is designed to enroll up to 30 healthy volunteers in a three-arm study to demonstrate the bioequivalence of safflower-produced insulin to comparator insulin products. The European authorities are the first major healthcare regulators to have published guidance documents that ensure insulin is eligible to receive approval through an abbreviated regulatory path. Separately, the U.S. FDA has advised SemBioSys that safflower-produced insulin is eligible to receive approval through an abbreviated 505(b)(2) approval process.

The world market value for insulin is estimated to be in excess of US$7.1 billion today and the demand for insulin is projected to increase due to two factors. The growing incidence of diabetes combined with the expanded use of insulin therapy is expected to almost double insulin demand over the next five years and increase the global insulin market to over $15 billion by 2012. SemBioSys' plant-made insulin is expected to offer substantial capital and cost-of-goods reductions with the potential to enter the market as a low-cost, easily expandable source of insulin to meet exploding global demand.

About SemBioSys Genetics Inc.

Calgary, Alberta-based SemBioSys Genetics Inc. is a biotechnology company developing protein-based pharmaceuticals for metabolic and cardiovascular diseases. The Company's lead pharmaceutical candidates, produced in the plant host safflower, are recombinant human insulin to serve the rapidly expanding global diabetes market and Apo AIMilano, a next generation cardiovascular drug. In addition to its pharmaceutical products, SemBioSys and its subsidiary, Botaneco Specialty Ingredients Inc., are developing a series of non-pharmaceutical products addressing human topical, nutritional
'/>"/>

0

GOOD

Page: 1 2 3
Related biology technology :

1. SemBioSys updates Apo AI development program
2. SemBioSys to present insulin data at the Seventh Annual Diabetes Technology Meeting
3. SemBioSys announces 2007 third quarter results
4. SemBioSys signs option agreement for safflower-produced food ingredient
5. SemBioSys to present at the 10th Annual BIO CEO & Investor Conference
6. SemBioSys awarded key patent for the production of oleosome emulsions by the European Patent Office
7. SemBioSys GLA Partner Enters Strategic Alliance for the Sales and Marketing of GLA-Rich Safflower Oil
8. SemBioSys announces 2007 financial and operational results
9. SemBioSys initiates toxicology study for safflower-produced insulin
10. SemBioSys receives milestone payments from AVAC Ltd.
11. SemBioSys announces first quarter 2008 financial and operational results

Post Your Comments:

SemBioSys eligible to proceed with Phase I/II plant-produced insulin trial after submiss...(ourth quarterof 2008. Prior to proceedin...)